Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Metastatic Breast Cancer
In brief
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Key facts
- Study ID
- NCT04115306
- Run by
- Phoenix Molecular Designs
- People needed
- 61
- Starts
- 2019-11-14
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
- City of Hope — Duarte, California, United States
- City of Hope Orange County, Lennar — Irvine, California, United States
- University of California, Los Angeles (UCLA) — Los Angeles, California, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- City of Hope Chicago — Zion, Illinois, United States
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- Profound Research — Farmington Hills, Michigan, United States
- Ohio State University — Columbus, Ohio, United States
- South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.